The American Cancer Society (ACS) has announced a fundamental update to its medical guidelines regarding the early detection of prostate cancer, shifting from a "shared decision-making" approach to recommending routine prostate-specific antigen (PSA) screening for men.
Details of the New Recommendations
According to the updated guidelines, men at average risk are advised to undergo PSA screening every two years starting at age 50 and continuing until age 69. For higher-risk groups, the society has established stricter criteria:
- Black men: Advised to begin annual screening at age 45 due to higher incidence rates.
- Those with a family history: Non-Black individuals who have a first-degree relative diagnosed with the disease before age 65, or those with more than one affected relative, are advised to begin annual screening at age 45.
- Limited family history cases: If there is only one relative diagnosed with the disease at age 65 or older, it is recommended to begin screening at age 45, but every two years.
For men between the ages of 70 and 74, the society recommends consulting a physician to evaluate the continuation of screening, while it does not recommend screening for those aged 75 and older.
Why This Change Matters
This shift comes after years of relying on a 2010 policy that did not mandate universal screening, but rather left the matter to the discretion of the physician and patient. The society justifies this change by citing new scientific evidence confirming that routine screening contributes to saving lives, alongside advancements in management techniques that reduce the risks of overdiagnosis and unnecessary treatments, which can lead to side effects such as erectile dysfunction and urinary incontinence.
Safety and Diagnostic Procedures
The society has established "guardrails" to ensure diagnostic accuracy, recommending that the PSA test be repeated if results are elevated (3 ng/mL for those under 70, and 6.5 ng/mL for those older) before taking any additional medical action. If results remain elevated, it is recommended to utilize prostate MRI or validated biomarker tests to assess risk, limiting the use of prostate biopsies to cases that strongly indicate the presence of cancer.
The society emphasizes that active surveillance should be the primary management strategy for cases showing low risk of growth or spread, allowing for the protection of patients from unnecessary surgical interventions while ensuring effective intervention in cases of aggressive cancer.